DDInter998 DDInter119
Ivermectin is a semi-synthetic antiparasitic medication derived from avermectins, a class of highly-active broad-spectrum antiparasitic agents isolated from the fermentation products of _Streptomyces avermitilis_. Ivermectin itself is a mixture of two avermectins, comprising roughly 90% 5-O-demethyl-22,23-dihydroavermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1a</sub>) and 10% 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro­-25-(1-methylethyl)avermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1b</sub>). Ivermectin is mainly used in humans in the
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Ivermectin {u} (Compound) binds {v} (Gene) NR1H4
Ivermectin {u} (Compound) upregulates {v} (Gene) TRAPPC6A
Ivermectin {u} (Compound) downregulates {v} (Gene) HSPD1
Ivermectin {u} (Compound) causes {v} (Side Effect) Eosinophilia
Ivermectin (Compound) binds NR1H4 (Gene)
Ivermectin (Compound) upregulates TRAPPC6A (Gene)
Ivermectin (Compound) downregulates HSPD1 (Gene)
Ivermectin (Compound) causes Eosinophilia (Side Effect)